April 6, 2021
MARCH 30 2021 Sean Whooley Glytec launches new insulin management system Glytec announced today that it introduced the latest version of its eGlycemic Management System (eGMS) for managing insulin. Waltham, Mass.-based Glytec’s eGMS is centered around the FDA-cleared Glucommander algorithm, which leverages real-time and historical data to recommend insulin dosing by learning each patient’s insulin sensitivity and anticipating future needs, …
MARCH 31 2021 Amy Reyes Diabetic Ketoacidosis With COVID-19 Fatal for Elderly and Obese Diabetes Patients Patients with diabetic ketoacidosis and a COVID-19 diagnosis died at increasingly higher rates than diabetic ketoacidosis patients without COVID-19, shows an analysis recently published in JAMA Network Open. Published online March 10 as a research letter, physicians led by Francisco J. Pasquel, MD, MPH, …
March 29, 2021
MARCH 23 2021 Medically reviewed by Michelle L. Griffith, MD — Written by Ashley Zlatopolsky 7 Things Certified Diabetes Educators Want You to Know About Managing Diabetes Taking care of yourself is an important part of managing type 2 diabetes. It often involves making changes to your diet and lifestyle, developing a workout plan, taking your medications, and monitoring your blood sugar level …
March 22, 2021
MARCH 10 2021 Kristen Monaco COVID-19 and Diabetic Ketoacidosis a Deadly Mix? — Nearly half of COVID-19-positive DKA patients over 65 died in the hospital COVID-19 appeared to increase risk of mortality in people hospitalized with diabetic ketoacidosis (DKA), researchers reported. In a comparison of hospitalized DKA patients from February to September 2020, 30% of those who also had COVID-19 …
MARCH 10 2021 Miriam Tucker COVID-19 Complicates Diabetic Ketoacidosis in Hospital The clinical course and prognosis of individuals hospitalized with diabetic ketoacidosis (DKA) are considerably worse among those who have COVID-19, new data show. In-hospital death was sixfold greater among patients with DKA who had COVID-19 compared with those who did not, and acute kidney injury was three times more common. “These findings …
November 13, 2018
Presented at the 18th Annual Diabetes Technology Meeting, the study found that patients treated using Glytec’s solution had 73.2% less hypoglycemia and no bounce backs once transferred from a CCU to a general ward.
With a shifting reimbursement landscape and acuity on the rise for hospitalized patients, the need to minimize length of stay and increase throughput in critical care units is a priority for health systems nationwide. A study conducted by Riverside Medical Center of Kankakee, Illinois, the flagship facility of Riverside Healthcare and the area’s only Magnet® recognized institution, found that by using Glytec’s eGlycemic Management System® (eGMS®), patients admitted to critical care units were transferred to general wards .25 days sooner and there were no “bounce backs,” or returns from general wards to critical care units. The study, presented at the 18th Annual Diabetes Technology Meeting, also found that severe hypoglycemia among patients in critical care units was 73.2% lower when using eGMS®.
January 23, 2018
Safety and efficacy of Glytec’s eGlycemic Management System® for diabetes therapy management, and its advantages over conventional methods, is further validated by four peer-reviewed studies.
Four new studies published in the January 2018 issue of Journal of Diabetes Science and Technology (JDST) demonstrate superior patient outcomes and organizational performance with Glytec’s eGlycemic Management System® (eGMS®) versus conventional, paper-based protocols. In all instances, which included both inpatient and outpatient settings, use of eGMS® for diabetes and insulin therapy management was observed to be safer and more effective than ‘usual care,’ with lower rates of hypoglycemia, faster resolution of diabetic ketoacidosis (DKA), expedited time to target glucose, and sustained reductions in A1c. Additionally, use of eGMS® led to substantive efficiency gains in provider workflows, fewer point-of-care tests, shorter lengths of stay, and full adoption of best practices, including 96% utilization of basal bolus insulin.
June 16, 2016
Wide range of studies further demonstrates significant impact in the emergency department, hospital and outpatient settings.
Glytec, the pioneer and leader in providing innovative, FDA-cleared glucose management software solutions, today announced that the company has presented five abstracts addressing a range of issues related to diabetes care at the American Diabetes Association’s 76th Scientific Sessions in New Orleans, Louisiana, June 10-14, 2016. The American Diabetes Association (ADA) brings together global leaders to discuss advancements in diabetes research and care.
June 5, 2016
The inclusion of a computer-guided program (Glucommander) as a component of diabetic ketoacidosis management was associated with significantly less hypoglycemia and faster time to normalization of blood glucose and bicarbonate than standard treatment of diabetic ketoacidosis, according to a new retrospective multicenter study.
The data were presented at the American Association of Clinical Endocrinologists (AACE) 25th Annual Scientific & Clinical Congress. The study also demonstrated a significant difference in length of hospital stay for patients treated with Glucommander compared with standard protocol (3.2 vs 4.5 days).
June 1, 2016
Experts demonstrate the ability of automated glucose management to significantly reduce rates of hypoglycemia and DKA.
Glytec, the pioneer and leader in providing innovative, FDA cleared glucose management software solutions, today announced that two abstracts addressing the approach to care for patients suffering from hypoglycemia and diabetic ketoacidosis (DKA) were presented at the American Association of Clinical Endocrinologists (AACE) 25th Annual Scientific and Clinical Congress, held from May 25-29th in Orlando, Florida.
May 31, 2016
When insulin dosages are calculated using computer algorithms to reach target blood glucose levels, hospitalized patients are less likely to have episodes of low blood sugar and recover sooner from diabetic ketoacidosis than when insulin dosages are calculated without an algorithm.
Those were key findings from two multisite studies presented at the American Association of Clinical Endocrinologists meeting, held May 25-29 in Orlando, Florida. “Computer algorithms facilitate doing the right thing,” said Dr. Joseph A. Aloi, professor of endocrinology and metabolism at Wake Forest Baptist Medical Center in Winston-Salem, North Carolina, and the studies’ principal investigator.
March 12, 2016
The use of insulin management software in hospital emergency departments can decrease hospital admissions for diabetic ketoacidosis (DKA) by 45%, according to a new study.
Hospital admissions were reduced by starting patients on IV insulin using Glucommander, a cloud-based insulin management software system, according to a new study. The study, conducted by researchers at Eastern Virginia Medical School, was published in Diabetes Technology & Therapeutics.
February 10, 2016
Study leveraging Glytec’s Glucommander IV demonstrated a lower rate of admissions and future hospitalizations, resulting in a cost savings of $78,000 within 12 months.
Glytec, the pioneer and leader in providing innovative glucose decision support software solutions for effective diabetes management, is pleased to share the results of a study conducted in collaboration with Wake Forest Medical School, Eastern Virginia Medical School, and Sentara Healthcare. The study demonstrated intensive insulin therapy used in emergency departments (ED) is useful in treating patients with mild to moderate diabetic ketoacidosis (DKA), resulting in a lower rate of admissions and future admissions to the hospital along with significant cost savings.
June 4, 2015
Company continues dramatic growth driven by its unprecedented, proven results.
Glytec, the pioneer and leader in providing innovative, FDA-cleared glucose management software solutions central to effective diabetes management, announces 13 additional health systems across the U.S. have recently selected the company’s eGlycemic Management System® (eGMS®). Collectively, they represent 37 new hospital implementations. eGMS® enables providers, payers, and patients to control glucose levels, and combat the well-documented, spiraling complications and costs associated with diabetes and hyperglycemia.
May 7, 2015
Wide range of studies further demonstrates significant impact in the emergency department, hospital and outpatient settings.
Glytec, the pioneer and leader in providing innovative, FDA-cleared glucose management software solutions central to effective diabetes management, today announced that several abstracts featuring the company’s eGlycemic Management Solution® (eGMS®) have been selected as poster presentations at the International Hospital Diabetes Meeting (IHDM), taking place from May 8-9th in San Francisco. Hosted by the Diabetes Technology Society, the fifth annual IHDM conference will showcase the optimal use of future and current technologies for people with diabetes in both critical and non-critical care settings.
May 16, 2014
Electronic monitoring of blood sugar levels may diminish hypoglycemia and reduce length of stay in hospitalized diabetic ketoacidosis (DKA) patients, researchers reported here.
In one study, patients monitored with the Glucommander system reduced episodes of hypoglycemia by 56%, Joseph Aloi, MD, director of the Strelitz Diabetes Center at Eastern Virginia Medical School in Norfolk, and colleagues reported at the American Association of Clinical Endocrinologists meeting here. In a second study, they showed that the same system reduced the overall hospital length of stay by nearly 2 1/2 days in patients with diabetic ketoacidosis.
